STOCK TITAN

Vanguard disaggregates holdings; reports 0 shares of Ingevity (NGVT)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting no beneficial ownership of Ingevity Corp common stock. The filing states 0 shares and 0% ownership after an internal realignment that disaggregated certain subsidiaries' holdings in reliance on SEC Release No. 34-39538. The signature block shows Ashley Grim, Head of Global Fund Administration.

Positive

  • None.

Negative

  • None.

Insights

Amendment records disaggregated reporting; Vanguard reports zero beneficial ownership.

The filing lists 0 shares and 0% beneficial ownership of Ingevity Corp common stock following an internal realignment and separate reporting by subsidiaries under SEC Release No. 34-39538. This is an administrative ownership reporting change rather than a market trade.

Interpretation depends on subsidiary filings: subsequent Schedule 13G/A or Form 13Fs from related Vanguard entities may show where holdings were reallocated. Cash‑flow treatment and any selling activity are not stated in the provided excerpt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does The Vanguard Group's Schedule 13G/A amendment for NGVT mean?

It reports that The Vanguard Group now shows 0 shares (0%) beneficial ownership of Ingevity Corp common stock. The amendment reflects an internal realignment and disaggregated reporting under SEC Release No. 34-39538.

Why does Vanguard report zero ownership of NGVT after the realignment?

Vanguard states certain subsidiaries will report beneficial ownership separately under SEC Release No. 34-39538. As a result, The Vanguard Group’s aggregated filing lists 0 shares and 0% ownership in this amendment.

Will this amendment show where Vanguard's NGVT holdings moved?

The amendment itself lists 0 shares for The Vanguard Group and notes subsidiaries now report separately. Specific subsidiary filings would show any reallocated holdings; they are not included in this excerpt.

Who signed the Schedule 13G/A amendment for NGVT on behalf of Vanguard?

The filing is signed by Ashley Grim, whose title is Head of Global Fund Administration. The signature block is dated in the excerpt and attests to the amendment.
Ingevity Corp

NYSE:NGVT

View NGVT Stock Overview

NGVT Rankings

NGVT Latest News

NGVT Latest SEC Filings

NGVT Stock Data

2.51B
34.71M
Specialty Chemicals
Chemicals & Allied Products
Link
United States
NORTH CHARLESTON